Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Background: The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment outcomes in patients with lymphoid malignancies. However, several studies have reported a relatively high rate of infection in adult patients following CD19-targeting CAR T-cell therapy, particularly in the first 28 days. Notably, acute human herpesvirus 6 B (HHV6B) reactivation occurs in up to two-thirds of allogeneic hematopoietic stem cell transplantation patients. Case presentations: Herein, we describe a report of HHV6B encephalitis/myelitis in three patients with relapsed/refractory diffuse large B-cell lymphoma post CAR T-cell therapy. All three patients received multiple lines of prior treatment (range: 2–9 lines). All patients presented with fever that persisted for at least 2 weeks after CAR-T cell infusion (CTI). Both the onset time and duration were similar to those of the cytokine release syndrome (CRS); nevertheless, the CRS grades of the patients were low (grade 1 or 2). Delirium and memory loss after CTI were the earliest notable mental presentations. Neurological manifestations progressed rapidly, with patients experiencing varying degrees of impaired consciousness, seizures, and coma. Back pain, lumbago, lower limb weakness and uroschesis were also observed in Patient 3, indicating myelitis. High HHV6B loads were detected in all Cerebral spinal fluid (CSF) samples using metagenomic next-generation sequencing (mNGS). Only one patient required high-activity antivirals and IgG intravenous pulse treatment finally recovered, whereas the other two patients died from HHV6B encephalitis. Conclusion: Considering its fatal potential, HHV6B encephalitis/myelitis should be urgently diagnosed post CAR-T cell-based therapy. Furthermore, hematologists should differentially diagnose these conditions from CRS or other immunotherapy-related neurotoxicities as early as possible. The results of this study demonstrate the potential of mNGS in the early diagnosis of HHV6B infection, particularly when the organism is difficult to culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HHV-6 reactivation can occur in up to two-thirds of hematopoietic stem cell transplant recipients, the prevalence of encephalitis among this cohort remains small, as low as 1.4% (27).”
From A post-implementation evaluation of BioFire FilmArray Meningitis/Encephalitis panel for pathogen detection in cerebrospinal fluid with a special focus on clinical significance of HHV-6 (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Supplementary diagnostic aids which can be utilized for HHV-6 meningoencephalitis include the presence of lymphocytic pleocytosis and elevated protein in CSF (27), although not consistently seen (25)”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · cited 1×
“…with relapsed or refractory disease who previously had limited treatment options, CAR-T cell therapy has shown impressive responses, including complete responses (CRs) in approximately 80% of patients with acute lymphoblastic leukemia (ALL) and 40–60% of those with aggressive lymphomas (1–4).”
BackgroundLee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 1×
“The late onset of neurotoxic symptoms in the patients here, with lumbar puncture (LP) performed 17–27 days after transplantation, is the primary clinical factor we would use in these patients to drive diagnostics for a secondary cause of altered mental status (20, 21).”
BackgroundCarstens, E. B. (2010) · Archives of Virology · doi:10.1007/s00705-009-0547-x · Cited by 1,135
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Adams, M. J., & Carstens, E. B. (2012) · Archives of Virology · doi:10.1007/s00705-012-1299-6 · Cited by 315
Park, J. H., Romero, F. A., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 276
Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., Gu, C., Zhang, S., Chen, L., Cheng, J., et al. (2020) · Blood · doi:10.1182/blood.2019000017 · Cited by 263 · cited 1×
“T cell was safe and efficacious in treating patients with R/R B-cell lymphomas (5, 6).”
BackgroundSelf-citation
Cited by
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy
Deschênes‐Simard, X., Santomasso, B., & Dahi, P. B. (2024) · Blood · doi:10.1182/blood.2024025679 · Cited by 34
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Vonberg, F. W., Malik, I., O'Reilly, M. A., Hyare, H., Carr, A. S., & Roddie, C. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-333924 · Cited by 26
Sassine, J., Siegrist, E. A., & Chemaly, R. F. (2025) · Viruses · doi:10.3390/v17010133 · Cited by 19
Abad, C. L. R., & Razonable, R. R. (2025) · Frontiers in Virology · doi:10.3389/fviro.2025.1641157 · Cited by 5
Perera, M., Varadhan, H., & Oon, A. (2026) · Microbiology spectrum · doi:10.1128/spectrum.00620-25 · Cited by 4
Metadata
- Authors
- Li, N., Zhang, R., Wang, J., Zhu, X., Meng, F., Cao, Y., Wang, G., & Yang, Y.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Wang, Gaoxiang
- Yang, Yang
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2024-02-29
- Volume
- 15
- Pages
- 1334000-1334000
- ISSN
- 1664-2295 (ISSN-L)
- PMC
- PMC10937551
- OpenAlex
- W4392292739
- Cited by
- 14
- References
- 36
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 2
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82000176, 81830008, 81630006, 81570197)
- Tongji University
- Topics
- Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, viral reactivation, cytokine release syndrome, differential diagnosis, metagenomic next-generation sequencing, antiviral therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. https://app.cochat.ai/papers/10.3389/fneur.2024.1334000
- The paper
- Li, N., Zhang, R., Wang, J., Zhu, X., Meng, F., Cao, Y., Wang, G., & Yang, Y. (2024). Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1334000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.